Immunotherapy of Cancer (Record no. 260586)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04510nam a22005055i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-4-431-55031-0 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20160615101158.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 160222s2016 ja | s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9784431550310 |
| -- | 978-4-431-55031-0 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-4-431-55031-0 |
| Source of number or code | doi |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | Alfaisal Main Library |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC254-282 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED062000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.994 |
| Edition number | 23 |
| 245 10 - TITLE STATEMENT | |
| Title | Immunotherapy of Cancer |
| Medium | [electronic resource] : |
| Remainder of title | An Innovative Treatment Comes of Age / |
| Statement of responsibility, etc | edited by Yoshiyuki Yamaguchi. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. 2016. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE STATEMENTS | |
| Place of production, publication, distribution, manufacture | Tokyo : |
| Name of producer, publisher, distributor, manufacturer | Springer Japan : |
| -- | Imprint: Springer, |
| Date of production, publication, distribution, manufacture | 2016. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | IX, 358 p. 46 illus., 8 illus. in color. |
| Other physical details | online resource. |
| 336 ## - CONTENT TYPE | |
| Content Type Term | text |
| Content Type Code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media Type Term | computer |
| Media Type Code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier Type Term | online resource |
| Carrier Type Code | cr |
| Source | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Part I Overview, History, Classification -- Chapter 1 Overview of Current Cancer Immunotherapy -- Part II BRMs and Crude Agents -- Chapter 2 Bacterial Preparations -- Chapter 3 Polysaccharides -- Chapter 4 BCG -- Part III Cytokines -- Chapter 5 αβ-T Cells -- Chapter 6 NKT Cell-Based Immunotherapy -- Chapter 7 Natural Killer Cells -- Chapter 8 γδ T Cell-Based Cancer Immunotherapy -- Chapter 9 Genetically engineered T cells -- Part IV Vaccine Therapy -- Chapter 10 Peptide Vaccine -- Chapter 11 Personalized Peptide Vaccine -- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies -- Chapter 13 Protein vaccine -- Chapter 14 Dendritic Cell-Based Vaccine for Cancer -- Part V Immunoadjuvants -- Chapter 15 CpG Motif -- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy -- Chapter 17 Novel Adjuvants -- Part VI Immunocheckpoints -- Chapter 18 Anti-CTLA-4 Ab -- Chapter 19 Anti-PD-1, PD-L1 Ab -- Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals -- Part VII Regulation of Immunosuppression -- Chapter 21 Regulatory T Cells -- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells -- Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials -- Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials -- Part IX Personalized Immunotherapy -- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cancer research. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Immunology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine & Public Health. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cancer Research. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Immunology. |
| 655 #7 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| Source of term | local |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yamaguchi, Yoshiyuki. |
| Relator term | editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9784431550303 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1007/978-4-431-55031-0">http://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1007/978-4-431-55031-0</a> |
| 912 ## - | |
| -- | ZDB-2-SME |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Library of Congress Classification |
| Koha item type | eBooks |
No items available.